Literature DB >> 16586357

Frequency and treatment-related predictors of thymidine-analogue mutation patterns in HIV-1 isolates after unsuccessful antiretroviral therapy.

Andrea De Luca1, Simona Di Giambenedetto, Laura Romano, Angela Gonnelli, Paola Corsi, Marco Baldari, Massimo Di Pietro, Stefano Menzo, Daniela Francisci, Paolo Almi, Maurizio Zazzi.   

Abstract

We investigated, in patients tested between 1991 and 2004, the patterns of mutually exclusive human immunodeficiency virus-1 thymidine-analogue mutations (TAMs) in 4039 reverse-transcriptase sequences with > or = 1 TAM. TAM pattern 1, which included M41L and L210W and excluded K70R and is coupled with more-extensive cross-resistance to drugs, became the most frequent pattern after 1996. In 1465 genotypes from 684 patients in whom highly active antiretroviral therapy (HAART) was unsuccessful, predictors of this pattern were the number of previous HAART regimens undergone (adjusted odds ratio [OR], 1.09 [95% confidence interval {CI}, 1.02-1.16]), use of stavudine/lamivudine (adjusted OR, 1.42 [95% CI, 1.05-1.99]), use of nevirapine (adjusted OR, 1.60 [95% CI, 1.14-2.24]), use of efavirenz (adjusted OR, 1.56 [95% CI, 1.08-2.27]), and use of ritonavir (adjusted OR, 1.35 [95% CI, 1.04-1.75]).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16586357     DOI: 10.1086/502976

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  5 in total

Review 1.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

2.  Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study.

Authors:  S Di Giambenedetto; C Torti; M Prosperi; N Manca; G Lapadula; G Paraninfo; N Ladisa; M Zazzi; M Trezzi; P Cicconi; P Corsi; P Nasta; R Cauda; A De Luca
Journal:  Infection       Date:  2009-08-07       Impact factor: 3.553

3.  Effect of the human immunodeficiency virus type 1 reverse transcriptase polymorphism Leu-214 on replication capacity and drug susceptibility.

Authors:  Maria Carmen Puertas; Maria Jose Buzón; Anna Artese; Stefano Alcaro; Luis Menendez-Arias; Carlo Federico Perno; Bonaventura Clotet; Francesca Ceccherini-Silberstein; Javier Martinez-Picado
Journal:  J Virol       Date:  2009-05-20       Impact factor: 5.103

4.  Virological response, HIV-1 drug resistance mutations and genetic diversity among patients on first-line antiretroviral therapy in N'Djamena, Chad: findings from a cross-sectional study.

Authors:  Chatté Adawaye; Joseph Fokam; Erick Kamangu; Hamit Mahamat Alio; Aoudalkarim Moussa Chahad; Fabrice Susin; Ali Mahamat Moussa; Tchombou Hig-Zounet Bertin; Abdelsalam Tidjani; Dolores Vaira; Michel Moutschen
Journal:  BMC Res Notes       Date:  2017-11-10

5.  Selecting anti-HIV therapies based on a variety of genomic and clinical factors.

Authors:  Michal Rosen-Zvi; Andre Altmann; Mattia Prosperi; Ehud Aharoni; Hani Neuvirth; Anders Sönnerborg; Eugen Schülter; Daniel Struck; Yardena Peres; Francesca Incardona; Rolf Kaiser; Maurizio Zazzi; Thomas Lengauer
Journal:  Bioinformatics       Date:  2008-07-01       Impact factor: 6.937

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.